Will HBM represent more than 30% of Micron's FY2026 total revenue?

HBM at ~22% of total revenue needs to jump to 30%, a 36% relative increase in share. The HBM revenue trajectory (>$1B to >$2B quarterly) shows strong growth, but the denominator effect from $75B annualized total revenue (FQ2 guidance) makes the 30% threshold demanding. CY2026 HBM supply fully contracted is bullish, but HBM4 ramp only begins in 2H 2026, making the full-year cumulative figure back-loaded and harder to achieve.

HBM4's higher trade ratios (>3:1, approaching 4:1 for HBM4E) serve a dual function: they increase HBM revenue per unit AND constrain non-HBM DRAM supply, which could moderate the denominator growth. With $35B HBM TAM in 2025 and Micron's ~21% share, that's ~$7.35B. If TAM grows even 30% to ~$45B in CY2026 and Micron holds share, that's ~$9.5B -- still well short of the ~$22.5B needed for 30% of $75B. The math requires either massive share gains or TAM outperformance.

The committee found reaching 30% 'requires significant acceleration' with 2/2 agreement. Current HBM run-rate of ~$8B annualized against ~$75B total revenue yields ~10.7% on a quarterly basis. Even if HBM doubles to $16B annualized, against $75B total that's only ~21%. To hit 30% cumulative for the full year ($22.5B of $75B) requires near-tripling from current run-rate, which the analysis facts do not support. The $100B TAM by 2028 projection (requiring ~40% CAGR) is the single most important unverifiable assumption and remains at E1 evidence level.

The math is straightforward and unfavorable. HBM is at ~22% of total revenue and needs an 8pp jump to 30% in one fiscal year. Total revenue is growing rapidly toward $75B annualized, meaning HBM revenue would need to reach ~$22.5B cumulative for FY2026. Current HBM run-rate is ~$8B. Even with HBM4 ramp and contracted supply, tripling HBM revenue while the denominator nearly doubles is a steep ask. The Myth Meter's NARRATIVE_REALITY_GAP = DIVERGING reinforces that 30% is where narrative meets reality, not where it's exceeded.

CY2026 HBM supply fully contracted on price and volume is the strongest bullish factor, and HBM4's higher trade ratios mean more revenue per DRAM bit consumed. However, the analysis notes only $143M in RPO beyond 1 year (0.4% of revenue), suggesting limited long-term contractual protection outside HBM. The unresolved debate on HBM demand durability (E0-E1 evidence, no historical precedent) adds material uncertainty. Even in optimistic scenarios, 30% cumulative for the full year is challenging given the denominator growth trajectory.

The committee found 'reaching 30% requires significant acceleration' with full agreement. HBM as % of DRAM was ~28% annualized in FQ4 FY2025 (~$8B vs $28.6B DRAM), but as % of total revenue only ~22%. This 6pp gap between DRAM-share and total-share reflects NAND and other segments diluting HBM's weight. For HBM to reach 30% of total, it would need to represent ~38-40% of DRAM, which is a steep ramp even with HBM4. Black Swan Beacon's ASSUMPTION_FRAGILITY = CONCENTRATED underscores the single-dependency on AI demand trajectory.

From 22% to 30% in one year is an 8pp jump requiring HBM revenue to significantly outpace total revenue growth. With total revenue at ~$75B annualized run-rate and HBM at ~$8B, the gap is too wide. More likely outcome is 24-27% range for FY2026.

The denominator effect dominates this question. Total revenue roughly doubling from FY2025's $37.4B toward ~$75B annualized means HBM revenue must roughly triple from ~$8B to ~$22.5B to maintain the 30% threshold. The committee's 2/2 consensus that this requires 'significant acceleration' and the Myth Meter's E1-rated TAM projection make this unlikely.

HBM4 ramp and fully contracted CY2026 supply are real tailwinds, but the question asks about cumulative FY2026, not exit rate. Even if HBM share reaches 28-30% by FQ4 FY2026, the full-year average would be lower due to earlier quarters running at ~22-25%. This cumulative framing biases the answer toward NO.